Effect of CAFfeine on Cognition in Alzheimer's Disease

Sporadic Alzheimer's disease is a multifactorial illness arising a major medico-economic stakes for our aging societies. There is currently no curative treatment available. Coffee is a complex beverage with psychostimulant properties whose main effective element, caffeine, has a pleiotropic effect on the central nervous system. Caffeine pharmacological properties enable its use like an Alzheimer's disease symptomatic treatment. Its supposed benefits mustn't obscure anxiety and insomnia caffeine effect at large dose, which Alzheimer's patients might be more vulnerable. The main study objective is to evaluate placebo-controlled caffeine efficacy (30 treatments weeks) on cognitive decline in Alzheimer's disease dementia at beginning to moderate stage (MMSE 16-24).

NCT Number	NCT04570085
Lead Sponsor	University Hospital, Lille Collaborators: Groupement Interrégional de Recherche Clinique et d'Innovation, Laboratory of excellence DISTALZ, Région Nord-Pas de Calais, France, Meo coffee
Conditions	Alzheimer Disease
Enrollment	248 participants
Start Date	2021-03-01
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-20